• About us
• Contact

Advertisement

Product › Details

Ofev®

	Next higher product group	nintedanib
	Status	2014-10-16 registration start
	Organisation	Boehringer Ingelheim (Group)

Record changed: 2023-07-10

Advertisement

More documents for tyrosine kinase inhibitor (TKI)

• [1] Qiagen N.V.. (8/7/23). "Press Release: Qiagen Receives FDA Approval for Companion Diagnostic to Blueprint Medicines’ Ayvakit (avapritinib) in Gastrointestinal Stromal Tumors". Venlo & Germantown, MD....
• [2] Zion Pharma Ltd.. (5/9/23). "Press Release: Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor". Hong Kong, Suzhou & Shanghai....
• [3] DeuterOncology N.V.. (1/19/23). "Press Release: DeuterOncology Closes €5.65M Series A Financing Round". Liège....
• [4] Bristol-Myers Squibb Company. (6/3/22). "Press Release: Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company". New York, NY & San Diego, CA....
• [5] NBE Therapeutics AG. (9/8/20). "Press Release: Exelixis and NBE-Therapeutics Enter into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer". Alameda, CA & Basel....
• [6] Boehringer Ingelheim. (2/28/20). "Press Release: Boehringer Ingelheim Receives Positive CHMP Opinion for Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease". Ingelheim....
• [7] AstraZeneca plc. (10/24/19). "Press Release: Year-to-Date and Q3 2019 Results"....
• [8] Roche. (8/16/19). "Press Release: FDA Approves Roche’s Rozlytrek (entrectinib) for People with ROS1-positive, MMetastatic Non-small Cell Lung Cancer and NTRK Gene Fusion-positive Solid Tumours". Basel....
• [9] Roche. (6/18/19). "Press Release: Japan Becomes the First Country to Approve Roche’s Personalised Medicine Rozlytrek". Basel....
• [10] Roche. (5/16/19). "Press Release: Roche’s Personalised Medicine Entrectinib Shrank Tumours Harbouring NTRK, ROS1 or ALK Gene Fusions in Children and Adolescents". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.